Boule Diagnostics AB (publ) (BOUL.ST)
SEK 7.99
(3.42%)
SEK 7.99
(3.42%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 249.71 Million SEK | 9.56% |
| 2022 | 227.9 Million SEK | 14.74% |
| 2021 | 198.63 Million SEK | 12.11% |
| 2020 | 177.18 Million SEK | -21.67% |
| 2019 | 226.21 Million SEK | 19.24% |
| 2018 | 189.71 Million SEK | -6.4% |
| 2017 | 202.68 Million SEK | 4.12% |
| 2016 | 194.67 Million SEK | 29.93% |
| 2015 | 149.82 Million SEK | 9.81% |
| 2014 | 136.44 Million SEK | 12.33% |
| 2013 | 121.46 Million SEK | -1.65% |
| 2012 | 123.5 Million SEK | 14.32% |
| 2011 | 108.03 Million SEK | 5.7% |
| 2010 | 102.21 Million SEK | 40.53% |
| 2009 | 72.73 Million SEK | 12.66% |
| 2008 | 64.56 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 68.3 Million SEK | 3.64% |
| 2024 Q3 | 61.1 Million SEK | 3.38% |
| 2024 Q2 | 59.1 Million SEK | -13.47% |
| 2023 Q3 | 57.9 Million SEK | -3.34% |
| 2023 Q4 | 65.9 Million SEK | 13.82% |
| 2023 FY | 249.7 Million SEK | 9.56% |
| 2023 Q1 | 66 Million SEK | -1.21% |
| 2023 Q2 | 59.9 Million SEK | -9.24% |
| 2022 Q1 | 56.9 Million SEK | -1.79% |
| 2022 Q3 | 51.1 Million SEK | -3.95% |
| 2022 FY | 227.9 Million SEK | 14.74% |
| 2022 Q4 | 66.8 Million SEK | 30.74% |
| 2022 Q2 | 53.2 Million SEK | -6.5% |
| 2021 Q3 | 50 Million SEK | 8.46% |
| 2021 Q2 | 46.1 Million SEK | 3.13% |
| 2021 Q4 | 57.93 Million SEK | 15.87% |
| 2021 FY | 198.63 Million SEK | 12.11% |
| 2021 Q1 | 44.7 Million SEK | 14.07% |
| 2020 Q4 | 39.18 Million SEK | -14.44% |
| 2020 Q1 | 55.2 Million SEK | 16.43% |
| 2020 Q2 | 37 Million SEK | -32.97% |
| 2020 FY | 177.18 Million SEK | -21.67% |
| 2020 Q3 | 45.8 Million SEK | 23.78% |
| 2019 Q3 | 66.4 Million SEK | 27.69% |
| 2019 Q4 | 47.41 Million SEK | -28.6% |
| 2019 Q1 | 54.1 Million SEK | 25.18% |
| 2019 FY | 226.21 Million SEK | 19.24% |
| 2019 Q2 | 52 Million SEK | -3.88% |
| 2018 Q4 | 43.21 Million SEK | -8.63% |
| 2018 FY | 189.71 Million SEK | -6.4% |
| 2018 Q3 | 47.3 Million SEK | -10.08% |
| 2018 Q2 | 52.6 Million SEK | 12.88% |
| 2018 Q1 | 46.6 Million SEK | -9.67% |
| 2017 Q2 | 43.6 Million SEK | -14.17% |
| 2017 Q1 | 50.8 Million SEK | 1.25% |
| 2017 Q3 | 56.9 Million SEK | 30.5% |
| 2017 Q4 | 51.58 Million SEK | -9.34% |
| 2017 FY | 202.68 Million SEK | 4.12% |
| 2016 Q2 | 47.7 Million SEK | 12.77% |
| 2016 Q3 | 54.5 Million SEK | 14.26% |
| 2016 Q4 | 50.17 Million SEK | -7.94% |
| 2016 Q1 | 42.3 Million SEK | 15.17% |
| 2016 FY | 194.67 Million SEK | 29.93% |
| 2015 Q3 | 41.4 Million SEK | 13.42% |
| 2015 Q1 | 35.2 Million SEK | -10.31% |
| 2015 Q4 | 36.72 Million SEK | -11.29% |
| 2015 Q2 | 36.5 Million SEK | 3.69% |
| 2015 FY | 149.82 Million SEK | 9.81% |
| 2014 Q2 | 31.3 Million SEK | -6.29% |
| 2014 Q4 | 39.24 Million SEK | 20.75% |
| 2014 FY | 136.44 Million SEK | 12.33% |
| 2014 Q1 | 33.4 Million SEK | 12.77% |
| 2014 Q3 | 32.5 Million SEK | 3.83% |
| 2013 FY | 121.46 Million SEK | -1.65% |
| 2013 Q2 | 33.18 Million SEK | 18.84% |
| 2013 Q4 | 29.61 Million SEK | -3.62% |
| 2013 Q3 | 30.73 Million SEK | -7.41% |
| 2013 Q1 | 27.92 Million SEK | -19.93% |
| 2012 Q2 | 32.62 Million SEK | 15.49% |
| 2012 Q4 | 34.87 Million SEK | 25.68% |
| 2012 Q1 | 28.25 Million SEK | 0.7% |
| 2012 FY | 123.5 Million SEK | 14.32% |
| 2012 Q3 | 27.75 Million SEK | -14.94% |
| 2011 Q4 | 28.05 Million SEK | 6.56% |
| 2011 Q2 | 25.59 Million SEK | -8.77% |
| 2011 Q1 | 28.05 Million SEK | -0.7% |
| 2011 FY | 108.03 Million SEK | 5.7% |
| 2011 Q3 | 26.32 Million SEK | 2.85% |
| 2010 Q4 | 28.25 Million SEK | 15.64% |
| 2010 FY | 102.21 Million SEK | 40.53% |
| 2010 Q1 | 22.11 Million SEK | 0.0% |
| 2010 Q3 | 24.43 Million SEK | -10.84% |
| 2010 Q2 | 27.4 Million SEK | 23.95% |
| 2009 FY | 72.73 Million SEK | 12.66% |
| 2008 FY | 64.56 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -4614.253% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 16.928% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 16.928% |
| Arcoma AB | 11.07 Million SEK | -2155.569% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | -78.391% |
| BICO Group AB (publ) | 1.83 Billion SEK | 86.359% |
| CellaVision AB (publ) | 463.04 Million SEK | 46.071% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -8232.132% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 978.839% |
| C-Rad AB (publ) | 66.01 Million SEK | -278.269% |
| Duearity AB (publ) | -4.17 Million SEK | 6076.879% |
| Dignitana AB (publ) | 58.97 Million SEK | -323.452% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 697.402% |
| Getinge AB (publ) | 13.43 Billion SEK | 98.141% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 597.267% |
| Iconovo AB (publ) | 17.57 Million SEK | -1320.633% |
| Integrum AB (publ) | 690.56 Thousand SEK | -36060.982% |
| Luxbright AB (publ) | -2.79 Million SEK | 9028.319% |
| Mentice AB (publ) | 236.38 Million SEK | -5.64% |
| OssDsign AB (publ) | 83.64 Million SEK | -198.54% |
| Paxman AB (publ) | 12.61 Million SEK | -1879.03% |
| Promimic AB (publ) | 38.51 Million SEK | -548.355% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 592.018% |
| SciBase Holding AB (publ) | 16.03 Million SEK | -1457.112% |
| ScandiDos AB (publ) | 47.55 Million SEK | -425.106% |
| Sectra AB (publ) | 557.55 Million SEK | 55.213% |
| Sedana Medical AB (publ) | 108.98 Million SEK | -129.135% |
| Senzime AB (publ) | 8.33 Million SEK | -2894.532% |
| SpectraCure AB (publ) | -9.22 Million SEK | 2807.514% |
| Stille AB | 132.17 Million SEK | -88.933% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 87.375% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 40.104% |